Trial Profile
Double-blind, double-dummy, randomised, multicentre, comparative study of the efficacy and tolerability of once daily 3.0 g mesalazine granules versus three times daily 1.0 g mesalazine granules in patients with active ulcerative colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2017
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Dr Falk Pharma
- 08 Jul 2011 New trial record